Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XH-30002 plus Afatinib in Advanced Esophageal Squamous Cell Carcinoma
NCT05927844Phase 1Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules, Drug Delivery Systems
01
Overview
Phase 1, open-label trial of XH-30002 in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Incidence of Treatment-Related Adverse Events and Serious Adverse Events at 6 months and Severity of Treatment-Related Adverse Events and Serious Adverse Events at 6 months. Status: unknown.
02
Drugs
XH-30002
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05927844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05927844.